

MACKIE RESEARCH CAPITAL CORPORATION

Suite 1920, 1075 West Georgia Street
Vancouver, British Columbia V6E 3C9

February 10, 2020

New Leaf Ventures Inc.
Suite 2200 – 885 West Georgia Street
Vancouver, BC V6C 3E8

Attention: Mr. Mike Stier, CEO and Director

Dear Sirs:

We understand that New Leaf Ventures Inc. (the "**Company**") wishes to appoint Mackie Research Capital Corporation (the "**Agent**") as its sole and exclusive agent to offer for sale by way of an initial public offering (the "**IPO**") to purchasers (the "**Purchasers**") resident in British Columbia, Alberta and Ontario, and such additional jurisdictions as the Company and the Agent may agree upon (defined herein as the "**IPO Jurisdictions**"). The IPO shall consist of up to 20,000,000 units (the "**IPO Units**") of the Company at a price of CDN\$0.25 per IPO Unit (the "**IPO Price**"), for aggregate gross proceeds of up to CDN\$5,000,000. Each IPO Unit will consist of one common share of the Company (each an "**IPO Share**") and one-half (1/2) of a common share purchase warrant (each whole warrant, an "**IPO Warrant**"). Each IPO Warrant will entitle the holder to acquire one additional common share of the Company (each an "**IPO Warrant Share**") at a price of \$0.40 per IPO Warrant Share for a period of twenty four (24) months from the IPO Closing (as defined herein). The IPO Warrants will be subject to an early expiry if the closing price of the common shares on the Canadian Securities Exchange (the "**Exchange**") is equal to or greater than \$0.60 per common share for a period of ten (10) consecutive trading days (the "**Early Expiry Event**").

The Agent has the right to increase the size of the IPO by up to 15% in IPO Units (the "**Agent's Option**") by giving written notice of the exercise of the Agent's Option, or part thereof, to the Company at any time until the date which is 30 calendar days following the IPO Closing.

Subject to the terms and conditions set forth in this Agency Agreement (this "**Agreement**"), the Company hereby appoints the Agent, and the Agent accepts such appointment, to act as the Company's sole and exclusive agent on a best efforts basis to sell the IPO Units pursuant to the Prospectus (as hereafter defined) in the IPO Jurisdictions.

The Agent may, through its United States registered broker-dealer affiliate (the "**U.S. Affiliate**"), offer the IPO Units for sale in the United States on behalf of the Company pursuant to Section 4(a)(2) of the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**"), and/or Rule 506(b) of Regulation D under the U.S. Securities Act ("**Regulation D**") to "accredited investors", as defined in Rule 501(a) of Regulation D ("**Accredited Investors**"), and to "qualified institutional buyers", as defined in Rule 144A under the U.S. Securities Act, that also qualify as Accredited Investors ("**Qualified Institutional Buyers**").

The Company shall also apply for listing on the Exchange.

1. Interpretation and Defined Terms

1.1 **Interpretation.** For the purposes of this Agreement, unless the context otherwise requires:

- (a) *Persons* – a reference to an individual shall include corporations, partnerships, trusts and other artificial entities and vice versa; a reference to any gender shall include the opposite gender; and any reference to a particular type of artificial entity shall include all other types of artificial entities;
- (b) *Number* – a reference to the singular in number shall include the plural and vice versa;
- (c) *Time* – a reference to any time shall refer to Vancouver time;
- (d) *Currency* – a reference to currency shall refer to lawful currency of Canada;
- (e) *Statutes* – a reference to a statute or "laws" shall include all rules, regulations, notices, orders, policies and other instruments made pursuant thereto, and all amendments, supplements, re-enactments and replacements thereof made from time to time; and
- (f) *Divisions and Headings* – the division of this Agreement into articles, sections and other sub-divisions, and the use of headings, is for convenience only and shall not affect the construction or interpretation of, or be used to limit the effect of, any of the terms and conditions of this Agreement.

1.2 **Defined Terms.** For purposes of this Agreement, the following terms shall have the ascribed meanings unless the context otherwise requires:

- (a) "**Accredited Investors**" has the meaning set out on page 1 hereof;
- (b) "**Acquisition Agreements**" has the meaning set out in Section 6.1(d) hereof;
- (c) "**Agent**" means Mackie Research Capital Corporation;
- (d) "**Agent's Commission**" means the commission to be paid to the Agent, as more particularly set out in section 3.1(a)(i) hereof;
- (e) "**Agent's Option**" has the meaning set forth on page 1 hereof, as more fully described in section 4.4 herein;
- (f) "**Agent's Units**" means the units of the Company having the same terms as the IPO Units, issuable upon due exercise of the Agent's Warrants, with each Agent's Unit consisting of one Agent's Unit Share and one-half Agent's Unit Warrant;
- (g) "**Agent's Unit Shares**" means the common shares of the Company issuable upon exercise of the Agent's Warrants;
- (h) "**Agent's Unit Warrants**" means the common share purchase warrants of the Company issuable upon due exercise of the Agent's Warrants;
- (i) "**Agent's Unit Warrant Shares**" means the common shares of the Company issuable upon exercise of the Agent's Unit Warrants;

- (j) "**Agent's Warrants**" means the warrants of the Company forming a part of the Agent's compensation and having the terms set out in section 3.1(b) hereof;
- (k) "**Agent's Warrant Certificate**" means the certificate representing and setting out the terms and conditions of the Agent's Warrants and the Agent's Unit Warrants (upon due exercise of the Agent's Warrants), in form and content satisfactory to the Agent and to the Company;
- (l) "**Agreement**" means this agency agreement, including all recitals herein and all schedules, appendices and exhibits attached hereto, as amended or supplemented from time to time;
- (m) "**Amendment**" means any amendment to the Preliminary Prospectus or the Prospectus;
- (n) "**Applicable Securities Laws**" means collectively the applicable securities laws of each of the IPO Jurisdictions and the United States, which shall include, without limitation, the laws of each such Province and State and each other jurisdiction in which the IPO Units are sold and the respective regulations promulgated under such laws;
- (o) "**Company**" means New Leaf Ventures Inc., including any material subsidiaries where applicable;
- (p) "**Corporate Finance Fee**" has the meaning set out in section 3.1(a)(ii) hereof;
- (q) "**Early Expiry Event**" has the meaning set out on page 1 hereof;
- (r) "**Exchange**" means the Canadian Securities Exchange;
- (s) "**Expenses**" has the meaning set out in section 11.1 hereof;
- (t) "**Final U.S. Private Placement Memorandum**" means the U.S. private placement memorandum, in a form satisfactory to the Agent and the Company, to which will be attached the Prospectus, to be delivered to offerees and/or purchasers of IPO Units who are, or are acting for the account or benefit of, persons in the United States or U.S. Persons, in accordance with Schedule "A" hereto;
- (u) "**Financial Statements**" has the meaning set out in section 5.1(bb) hereof;
- (v) "**Indemnified Parties**" has the meaning set out in section 13.1 hereof;
- (w) "**IPO**" means the offering and sale of the IPO Units to the public pursuant to the Prospectus and, as the context requires, the issue of the Agent's Warrants, all pursuant to the terms and conditions of this Agreement;
- (x) "**IPO Closing**" means the completion of the IPO, and in the event that such occurs in one or more tranches, then each such tranche shall be an "**IPO Closing**";
- (y) "**IPO Jurisdictions**" has the meaning set out on page 1 hereof;
- (z) "**IPO Price**" has the meaning set out on page 1 hereof;
- (aa) "**IPO Shares**" has the meaning set out on page 1 hereof;

- (bb) "**IPO Units**" has the meaning set out on page 1 hereof;
- (cc) "**IPO Warrant Indenture**" means the warrant indenture dated the date of IPO Closing between the Company and Odyssey Trust Company, as warrant agent;
- (dd) "**IPO Warrants**" has the meaning set out on page 1 hereof;
- (ee) "**IPO Warrant Certificate**" means a certificate representing and setting out the terms and conditions of the IPO Warrants;
- (ff) "**IPO Warrant Share**" has the meaning set out on page 1 hereof;
- (gg) "**Listing**" means the listing of the common shares of the Company on the Exchange;
- (hh) "**Listing Agreement**" means the listing agreement entered into between the Company and the Exchange in respect of the Listing in accordance with the policies of the Exchange;
- (ii) "**misrepresentation**" has the meaning ascribed to it by the Applicable Securities Laws;
- (jj) "**Passport System**" means the requirements and procedures set out in Multilateral Instrument 11-102: Passport System, of the Canadian Securities Administrators;
- (kk) "**Preliminary Prospectus**" means the preliminary prospectus of the Company relating to the IPO, as amended from time to time;
- (ll) "**Preliminary U.S. Private Placement Memorandum**" means the U.S private placement memorandum, in a form satisfactory to the Agent and the Company, to which will be attached a copy of the Preliminary Prospectus, to be delivered to offerees of the IPO Units who are, or are acting for the account or benefit of, persons in the United States or U.S. Persons in accordance with Schedule "A" hereto;
- (mm) "**President's List**" means a list of potential subscribers provided by the directors and officers of the Company in accordance with this Agreement;
- (an) "**Prospectus**" means the final prospectus of the Company relating to the IPO, as amended from time to time;
- (ao) "**Public Record**" has the meaning set out in section 5.1(e) hereof;
- (ap) "**Purchasers**" means, as the context requires, the purchasers of the IPO Units;
- (aq) "**Qualified Institutional Buyers**" has the meaning set out on page 1 hereof;
- (rr) "**Regulation D**" has the meaning set out on page 1 hereof;
- (ss) "**Regulation S**" means Regulation S under the U.S. Securities Act;
- (tt) "**Securities**" means, collectively, the IPO Units (including IPO Units sold pursuant to the exercise of the Agent's Option), IPO Shares, IPO Warrants, IPO Warrant Shares, Agent's Warrants, Agent's Units, Agent's Unit Shares, Agent's Unit Warrants and Agent's Unit Warrant Shares;

- (uu) "**Sub-Agents**" has the meaning set out in section 2.2 hereof;
 - (vv) "**Transaction Agreements**" has the meaning set out in section 5.1(m) hereof;
 - (aw) "**United States**" or "**U.S.**" means the United States of America, its territories and possessions, any state of the United States and the District of Columbia;
 - (ax) "**U.S. Affiliate**" has the meaning set out on page 1 hereof;
 - (yy) "**U.S. Memorandum**" means the Preliminary U.S. Private Placement Memorandum and/or the Final U.S. Private Placement Memorandum;
 - (zz) "**U.S. Person**" means a "**U.S. person**" as that term is defined in Regulation S; and
 - (aaa) "**U.S. Securities Act**" has the meaning set out on page 1 hereof.
- 1.3 Capitalized terms not otherwise defined herein shall have the meaning ascribed to such terms in the Prospectus, as amended from time to time.
- 2. Appointment**
- 2.1 Subject to the terms and conditions set forth in this Agreement, the Company hereby appoints the Agent, and the Agent accepts such appointment, to act as the Company's sole and exclusive agent on a best efforts basis to sell the IPO Units pursuant to the Prospectus in the IPO Jurisdictions. It is understood and agreed that the Agent is under no obligation to purchase any IPO Units, although the Agent may purchase IPO Units if it so desires.
- 2.2 The IPO is comprised of a subscription of up to 20,000,000 IPO Units. Notwithstanding any other terms of this Agreement, the Company acknowledges and agrees that all subscription funds received by the Agent will be returned to the Purchasers without interest or deduction if this Agreement or the IPO is otherwise terminated.
- 2.3 The Company acknowledges and agrees that the Agent may appoint other registered dealers as its agents (the "**Sub-Agents**") to assist in the IPO, and that the Agent may determine the remuneration payable by the Agent to the Sub-Agents, including a division of the Agent's Warrants. The Agent shall ensure that any Sub-Agents comply with the covenants and obligations made by the Agent to the Company herein. The Company acknowledges and agrees that each Sub-Agent shall have the benefit of the covenants and obligations made by the Company to the Agent herein.
- 2.4 The Agent understands that the IPO Units are not being registered under the United States *Securities Act of 1933*, as amended, and represents that it has not offered or sold and agrees that it will not offer, sell or deliver at any time, directly or indirectly, in the United States (which term, as used herein, includes its territories or possessions) or to or for the account of any person whom the Agent knows, or has reason to believe, is a United States national or resident thereof, any of the IPO Units, other than on a private placement basis in accordance with the terms and conditions of this Agreement and Schedule "A" hereto. The Agent further agrees that it will require any Sub-Agent who offers and sells any of the IPO Units to agree to comply with this requirement.

3. Compensation

3.1 In consideration of the services to be rendered by the Agent in connection with the qualification, issue and sale of the IPO Units, including but not limited to acting as financial advisor to the Company, assisting the Company in the preparation of relevant documentation and assisting the Company in preparing, finalizing and obtaining requisite regulatory approvals for the Preliminary Prospectus and Prospectus, the Company shall:

- (a) on the date(s) of the IPO Closing:
 - (i) pay to the Agent a cash commission (the "**Agent's Commission**") equal to 8% of the gross proceeds from the IPO from the Purchasers not on the President's list and 2% of the gross proceeds from the IPO from the Purchasers on the President's List; and
 - (ii) pay to the Agent a corporate finance fee (the "**Corporate Finance Fee**") of \$30,000 plus GST, payable in cash (of which a non-refundable amount of \$15,750 including GST has been received by the Agent); and
- (b) on the date(s) of the IPO Closing, grant to the Agent a number of non-transferable warrants (the "**Agent's Warrants**") as is equal to 8% of the number of IPO Units sold to the Purchasers not on the President's List and 4% of the number of IPO Units sold to the Purchasers on the President's List, each entitling the holder thereof to purchase one Agent's Unit at a price of \$0.25 per Agent's Unit for a period of 24 months after the date of the Listing.

3.2 The Agent's Warrants shall be qualified pursuant to the Prospectus.

4. Nature of the IPO

4.1 The Company agrees that the Purchasers shall have the benefit of and are entitled to rely on all representations, warranties, covenants and conditions made by the Company to or for the benefit of the Agent and/or Purchasers herein or in any certificates or documents submitted pursuant to or in connection with the transactions provided for herein as if the same had been repeated and made to the Purchasers and notwithstanding any investigation which the Agent or the Purchasers may undertake or which may be undertaken on the Agent's or any Purchaser's behalf.

4.2 The IPO Units will be offered for sale pursuant to the Prospectus in the IPO Jurisdictions at the IPO Price. The Company will file the Preliminary Prospectus and Prospectus with the applicable securities regulatory authorities in the IPO Jurisdictions in accordance with the Applicable Securities Laws, and will use best efforts to obtain all required receipts for, or Passport system decision documents approving, each of the Preliminary Prospectus and Prospectus.

4.3 The Company shall also apply for listing on the Exchange.

4.4 The Company shall grant to the Agent the Agent's Option to offer and sell up to an additional 3,000,000 IPO Units, being 15% of the maximum number of IPO Units to be sold pursuant to the IPO, at \$0.25 per IPO Unit. The notice exercising the Agent's Option, which may be exercised in whole or in part by the Agent, at any time until the date that is 30 calendar days following the IPO Closing, shall be given by the Agent to the Company in the manner set out in section 18.2 hereof and shall specify the number of IPO Units to be sold under the Agent's Option.

5. Representations and Warranties of the Company

- 5.1 The Company represents and warrants to the Agent and Purchasers, and acknowledges that the Agent and Purchasers are relying on such representations and warranties in, respectively, selling or purchasing the IPO Units, and further agrees that such representations and warranties are contractually enforceable against the Company by the Purchasers notwithstanding that the Purchasers are not parties to this Agreement, that:
- (a) the Company has no subsidiaries, other than as disclosed in the Prospectus;
 - (b) the Company has been duly and validly incorporated and organized and is duly and validly existing and in good standing under the laws of its jurisdiction of incorporation, amalgamation or other formation, as the case may be;
 - (c) at the time of the IPO Closing, the Company will be a reporting issuer in the IPO Jurisdictions and will not be a reporting issuer or equivalent in any jurisdiction other than such IPO Jurisdictions;
 - (d) at the time of the IPO Closing, the Company will have filed all documents that it is required to have filed under the continuous disclosure and other requirements of the Applicable Securities Laws and the Exchange, including but not limited to all annual and interim financial information, management discussion and analysis, annual reports, annual information forms, information circulars, press releases disclosing material changes and material change reports, and no material change relating to the Company will have occurred with respect to which the requisite material change report has not been filed and no such material change report will have been made on a confidential basis, and to the best of the Company's knowledge it will not be in default of any Applicable Securities Laws in any material respect;
 - (e) except as disclosed in the Preliminary Prospectus or Prospectus, at the time of the IPO Closing, the Preliminary Prospectus, the Prospectus, offering memoranda, filing statements, financial statements, management discussion and analysis, annual reports, annual information forms, information circulars, press releases, material change reports, to the extent applicable, and all other documents and information as applicable filed under Applicable Securities Laws and with the Exchange (collectively, the "**Public Record**") will be, at the respective dates thereof, in all material respects accurate and, at such dates, omit no facts, the omission of which makes the Public Record, or any particulars therein, incorrect or misleading;
 - (f) at the time of the IPO Closing, the common shares of the Company (including the IPO Shares) will be conditionally approved for listing on the Exchange, and to the best of the Company's knowledge, the Company will not be in default of any of the listing requirements or policies of the Exchange in any material respect;
 - (g) at the time of the IPO Closing, Odyssey Trust Company will be duly and validly appointed as the registrar and transfer agent of the common shares of the Company;
 - (h) the authorized and issued capital of the Company is as disclosed in the Preliminary Prospectus or Prospectus, as applicable, and the issued securities of the Company are all duly authorized, issued and outstanding as fully paid and non-assessable securities, as at the respective dates thereof;

- (i) at the time of the IPO Closing, no shares and no rights of any kind to acquire shares of the Company will have been issued except as disclosed in the Preliminary Prospectus or Prospectus, as applicable, after the date of the Financial Statements other than pursuant to any agreement in effect at the date of the Financial Statements and of which the Agent has written notice, without the prior written consent of the Agent, not to be unreasonably withheld or delayed;
- (j) at the time of the IPO Closing, no options, warrants, agreements or other rights for the purchase, subscription or issuance of shares or other securities of the Company or securities convertible or exchangeable for shares or other securities of the Company will be authorized or agreed to be issued or outstanding other than as disclosed in the Preliminary Prospectus or Prospectus, as applicable;
- (k) the Company has full corporate power and authority to undertake the IPO and to create, offer, sell and issue the Securities, and all such corporate action has been taken to authorize such undertaking, creation, offer, sale and issuance;
- (l) at the time of the IPO Closing:
 - (i) the IPO Shares will be duly and validly authorized and issued as fully paid and non-assessable shares of the Company;
 - (ii) the IPO Warrants will be duly and validly authorized, created and issued;
 - (iii) the IPO Warrant Shares will be duly and validly authorized and reserved for issue upon exercise of the IPO Warrants, and when issued upon exercise of the IPO Warrants in accordance with the terms of the IPO Warrant Indenture and, if applicable, the IPO Warrant Certificates and receipt of full payment therefor, the IPO Warrant Shares will be duly and validly issued as fully paid and non-assessable shares of the Company;
 - (iv) the Agent's Warrants will be duly and validly authorized, created and issued;
 - (v) the Agent's Unit Shares will be duly and validly authorized and reserved for issue upon exercise of the Agent's Warrants, and when issued upon exercise of the Agent's Warrants in accordance with the terms of the Agent's Warrant Certificates and receipt of full payment therefor, the Agent's Unit Shares will be duly and validly issued as fully paid and non-assessable shares of the Company;
 - (vi) the Agent's Unit Warrants will be duly and validly authorized and reserved for issue upon exercise of the Agent's Warrants;
 - (vii) the Agent's Unit Warrant Shares will be duly and validly authorized and reserved for issue upon exercise of the Agent's Unit Warrants, and when issued upon exercise of the Agent's Unit Warrants in accordance with the terms of the Agent's Warrant Certificates and receipt of full payment therefor, the Agent's Unit Warrant Shares will be duly and validly issued as fully paid and non-assessable shares of the Company; and
 - (viii) at all times after the IPO Closing until the exercise or expiry of all of the IPO Warrants, the Agent's Warrants and the Agent's Unit Warrants, the Company

shall have a sufficient number of common shares reserved and available for issuance to satisfy its obligations under the IPO Warrants, the Agent's Warrants and the Agent's Unit Warrants, respectively;

- (m) the Company has full corporate power and authority to enter into, execute, deliver and perform its obligations under each of the agreements set out under "Material Contracts" in the Prospectus to which the Company is a party, the U.S. Accredited Investor Agreements with Purchasers who are Accredited Investors (the form of which is attached as Exhibit "A" to the U.S. Memorandum), the U.S. QIB Agreements with Purchasers who are Qualified Institutional Buyers (the form of which is attached as Exhibit "B" to the U.S. Memorandum), the IPO Warrant Indenture and, if applicable, the IPO Warrant Certificates, and the Agent's Warrant Certificates (collectively, the "**Transaction Agreements**"), and all such corporate action has been taken or will be taken to authorize all such entering into, execution, delivery and performance;
- (n) the Company shall be deemed to be making to the Agent the representations and warranties of New Leaf USA Inc. in section 3.2 of the Share Purchase Agreement, and any certificates or documents delivered pursuant to or in connection with the closing of the transactions provided for therein as if the same had been repeated and made to the Agent and notwithstanding any investigation which the Agent may undertake or which may be undertaken on the Agent's behalf;
- (o) the Company has or will have full corporate power and authority to prepare, execute and deliver the Preliminary Prospectus, Prospectus, Preliminary U.S. Private Placement Memorandum and Final U.S. Private Placement Memorandum, and all such corporate action has been or will be taken to authorize such preparation, execution and delivery;
- (p) each of the Transaction Agreements, Preliminary Prospectus, Prospectus, Preliminary U.S. Private Placement Memorandum and Final U.S. Private Placement Memorandum has been, or will be upon execution and delivery thereof by the Company, duly and validly authorized, executed and delivered by the Company, and each of the Transaction Agreements constitutes, or will constitute upon execution and delivery thereof by the Company, a legal, valid and binding obligation of the Company enforceable against it in accordance with each of their respective terms subject to laws affecting enforceability including, but not limited to, bankruptcy, insolvency, moratorium, reorganization and equitable remedies;
- (q) the Company is not in default or breach of, and the execution and delivery by the Company of each of the Transaction Agreements, Preliminary Prospectus, Prospectus, Preliminary U.S. Private Placement Memorandum and Final U.S. Placement Memorandum and the performance of the transactions contemplated by the Transaction Agreements, do not and will not result in a default or breach of, and do not create a state of facts which after notice or lapse of time or both will result in a default or breach of, and do not and will not conflict with, any of the terms, conditions or provisions of (i) the constating documents, articles or any resolutions of the Company, (ii) any indenture, contract, agreement (written or oral), lease, instrument or other document to which the Company is a party or by which the Company is or will be contractually bound as of the time of the IPO Closing, or (iii) to the best of the Company's knowledge, any statute, rule, regulation, policy, judgment, decree or order of any court, governmental authority or administrative body of any kind whatsoever having jurisdiction over the Company or its properties or assets;

- (r) insofar as the Company is aware after due inquiry, no consent of any third party is required in connection with the transactions contemplated by the Transaction Agreements, other than approvals of the Exchange and securities regulatory authorities in the IPO Jurisdictions;
- (s) the Company has all requisite corporate power and authority and has taken all necessary corporate action to authorize it to carry on its business as now conducted and as currently proposed to be conducted and to own, lease and operate its property and assets, and the Company is duly registered, licensed and otherwise qualified to carry on its business and to own its property and assets, and is in good standing, in the jurisdictions where it carries on its business and owns, leases and operates its property and assets;
- (t) the Company holds all registrations, licenses, permits, consents or qualifications (whether governmental, regulatory or otherwise) required in order to enable its business to be carried on as now conducted, as set out in the Preliminary Prospectus or Prospectus, and (i) all such registrations, licenses, permits, consents and qualifications are valid and subsisting and in good standing, and (ii) the Company has not received any notice of proceedings relating to the revocation or modification of any such registration, license, permit, consent or qualification which, if the subject of an unfavourable decision, ruling or finding, would have a material adverse effect (financial or otherwise) on the assets, properties, liabilities, obligations, conduct of the business, operations, affairs, condition or prospects of the Company;
- (u) the Company has conducted and is conducting its business in compliance in all material respects with all applicable laws, bylaws, rules, regulations and other lawful requirements of each jurisdiction in which its business is carried on and of any governmental or regulatory bodies which are applicable to the Company, and the Company is not aware of any such law, bylaw, rule, regulation or lawful requirement presently in force or proposed to be brought into force in any jurisdiction in which its business is carried on or by any governmental or regulatory body which the Company anticipates it will be unable to comply with without having a material adverse effect on its business;
- (v) the Company is the beneficial owner of or has the right to acquire the interests in the business, properties and assets as disclosed in the Preliminary Prospectus or Prospectus, and has good and marketable title thereto free and clear of any and all liens, charges, pledges, security interests and other claims, demands and encumbrances of any nature or kind whatsoever except as disclosed in the Preliminary Prospectus or Prospectus, and to the knowledge of the Company, any and all agreements pursuant to which the Company will hold any such interest in such business, properties or assets have been duly authorized, executed and delivered by the parties thereto, are legal, valid and binding obligations of the parties thereto enforceable in accordance with their respective terms and are in good standing in all material respects according to their terms, and any and all such business, properties and assets are not in default in any material respect of, and are in good standing in all material respects under, the applicable statutes and regulations of the jurisdictions in which they are situated;
- (w) insofar as the Company is aware after due inquiry, the Equipment is in good condition and suitable for its intended use or purpose;
- (x) the Company is not a party to any material contracts other than as disclosed in the Prospectus, and to the knowledge of the Company, each of the material contracts

disclosed in the Preliminary Prospectus or Prospectus to which the Company is a party has been duly authorized, executed and delivered by the parties thereto and is a legal, valid and binding obligation of the parties thereto enforceable in accordance with their respective terms, and is in good standing in all material respects according to their respective terms;

- (y) except as disclosed in the Preliminary Prospectus or Prospectus, no actions, suits, inquiries, investigations or other proceedings exist or are pending or, to the knowledge of the Company or its directors and officers, are contemplated or threatened to which any of the Company, its directors or its officers is a party or is subject, or to which the property of the Company is subject that would result individually or in the aggregate in any material adverse change in or have a material adverse effect on (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) the business, operations, affairs, prospects, condition, capital or control of the Company, or on the Prospectus or the Transaction Agreements, or which would materially impair the ability of the Company to consummate the transactions contemplated by the Transaction Agreements or to duly perform and observe its covenants and obligations under the Transaction Agreements;
- (z) since incorporation, the Company has not entered into a transaction material in nature to the Company other than as disclosed in the Prospectus, and if required by law or generally accepted accounting standards, all of the material transactions of the Company have been promptly and properly recorded or filed in or with its respective books and records;
- (aa) the Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management's general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with applicable laws and to maintain asset accountability; (iii) access to financial assets is permitted only in accordance with management's general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
- (bb) the auditors of the Company who have been engaged to audit the Financial Statements of the Company and deliver their report with respect thereto, are and will be independent public accountants;
- (cc) the audited financial statements of the Company and the interim unaudited financial statements of the Company if any delivered to the Agent and included in the Preliminary Prospectus and Prospectus (collectively the "**Financial Statements**") are complete and accurate in all material respects, and present fairly, in all material respects, the financial position of the Company as at the dates set out therein and the results of its operations and the changes in its financial position for the periods then ended, and are prepared in accordance with International Financial Reporting Standards, consistently applied throughout the periods covered thereby;
- (dd) except as disclosed in the Preliminary Prospectus or Prospectus, subsequent to the respective dates as of which information is given therein, the Company has not incurred or accrued any material liabilities or obligations (actual, anticipated, contingent, proposed

or threatened, whether financial or otherwise) or entered into any transaction not in the ordinary course of the business;

- (ee) except as disclosed in the Preliminary Prospectus or Prospectus, subsequent to the respective dates as of which information is given therein, there has been no material change in or affecting, nor any material facts, transactions, events or occurrences, which could have a material effect on (actual, anticipated, threatened, proposed or prospective, whether financial or otherwise) the assets, properties, liabilities, obligations, business, affairs, results of operations or financial position (absolute, accrued, contingent or otherwise) or the capital or control of the Company;
- (ff) at the time of the IPO Closing, the Company will not have, directly or indirectly, declared or paid any dividend or declared or made any other distribution on any of its common shares or securities of any class, or, directly or indirectly, redeemed, purchased or otherwise acquired any of its common shares or securities or agreed to do any of the foregoing;
- (gg) there is not, in the constating documents or the articles of the Company or in any agreement, mortgage, note, debenture, indenture or other agreement, instrument or document to which the Company is a party, any restriction upon or impediment to the declaration or payment of dividends by the directors of the Company or the payment of dividends by the Company to the holders of its common shares;
- (hh) to the extent applicable, by the IPO Closing, the Company will have filed all tax returns and reports required to be filed, and paid all such taxes and related charges of any kind whatsoever due and payable or established on its books and records reserves that are adequate for the payment of all such taxes and related charges of any kind whatsoever not yet due and payable, and, except as disclosed in the Preliminary Prospectus or Prospectus, there are no liens for taxes on the assets of the Company; there are no audits known by the Company's management to be pending on the tax returns of the Company (whether federal, provincial, local or foreign), and there are no claims which have been or, to the knowledge of the Company, may be asserted relating to any such tax returns, which audits and claims, if determined adversely, would result in the assertion by any government agency of any deficiency that would have a material adverse effect (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) on the assets, properties, liabilities, obligations, business, operations, affairs, prospects, results of operations or financial position (absolute, accrued, contingent or otherwise), or the capital or control of the Company;
- (ii) except as disclosed in the Preliminary Prospectus or Prospectus, none of the Canada Revenue Agency, the Internal Revenue Service of the United States nor any other taxation authority in any jurisdiction has asserted or, to the best of the Company's knowledge, threatened to assert any assessment, claim or liability for taxes due or to become due in connection with any review or examination of the tax returns of the Company filed for any year which would have a material adverse effect (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) on the assets, properties, liabilities, obligations, business, operations, affairs, prospects or financial condition (absolute, accrued, contingent or otherwise) or the financial position or results of operations of the Company;

- (jj) all filings made by the Company under which it has received or is entitled to government loans or incentives have been made in accordance with, in all material respects, applicable legislation and contain no misrepresentations of a material fact or omit to state any material fact which could cause any amount previously paid to the Company or previously accrued on the accounts thereof to be recovered or disallowed;
- (kk) the Company holds or has the right to acquire the intellectual property rights and interests described in the Preliminary Prospectus and Prospectus, and:
 - (i) to the knowledge of the Company after due inquiry, such intellectual property rights and interests are held under valid, subsisting and enforceable documents or other recognized and enforceable agreements or instruments, sufficient to permit the Company, upon completion of the Acquisition Transaction, to carry out the proposed business as set out in the Prospectus;
 - (ii) to the knowledge of the Company after due inquiry, all such intellectual property rights and interests have, to the extent practicable, been validly recorded in accordance with all applicable laws and are valid and subsisting;
 - (iii) to the knowledge of the Company after due inquiry, the Company's business, as now conducted does not, and as currently proposed to be conducted will not, infringe or conflict with in any material respect patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses or other intellectual property or franchise right of any person;
 - (iv) there are no current outstanding claims against the Company alleging the infringement by the Company of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property right or franchise right of any person; and
 - (v) to the knowledge of the Company after due inquiry, each of such intellectual property rights and interests, and each of the agreements, instruments and other documents relating thereto referred to above is currently in good standing in all material respects;
- (ll) no person has taken or, to the best of the Company's knowledge, has threatened or is in contemplation of, any action which would in any way prevent, limit, restrict or cause interference with any business which the Company currently proposes to carry out as set out in the Prospectus;
- (mm) no labour dispute or problem with the employees of the Company exists or, to the knowledge of the Company, is threatened or imminent, and the Company is not aware of any existing or imminent labour disturbance by the employees of any of its principal suppliers, customers or contractors that could have a material adverse effect (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) on the assets, properties, liabilities, obligations, business, operations, affairs, prospects, results of operations or condition (financial or otherwise), or capital or control of the Company, whether or not arising from transactions in the ordinary course of business;
- (an) as at the respective dates (i) on which the certificate page of the Preliminary Prospectus and Prospectus were or will be executed by the Agent, and (ii) on which the Preliminary

Prospectus and Prospectus were or will be filed with the securities regulatory authorities of the IPO Jurisdictions, the Preliminary Prospectus and the Prospectus, as the case may be, fully complied with or will fully comply with requirements of the Applicable Securities Laws, provided or will provide full, true and plain disclosure of all material facts relating to the Company in accordance with the Applicable Securities Laws and did not or will not contain any misrepresentation or any untrue, false or misleading statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances in which they were made, not untrue, false or misleading;

- (ao) the Company has taken or will take all steps as may be necessary to fully comply with the requirements of corporate laws and securities laws, including but not limited to the Applicable Securities Laws, in relation to all matters relating to the IPO, the Preliminary Prospectus, the Prospectus, the offer, sale, issue, delivery and trading of its securities generally and the Securities in particular, and the Transaction Agreements, and the Company is entitled to avail itself of the applicable prospectus and registration exemptions available under the Applicable Securities Laws in respect of the distribution of any IPO Warrant Shares, Agent's Unit Shares, Agent's Unit Warrants and Agent's Unit Warrant Shares;
- (ap) there is no current or pending, or to the best of the Company's knowledge, contemplated or threatened order, ruling or other determination by any securities commission, stock exchange or similar regulatory authority or any other competent authority having the effect of ceasing, suspending, prohibiting or preventing the trading of any securities of the Company, of any trading by any one or more directors, officers, other insiders or promoters of the Company, or the creation, offer, sale issuance or delivery of any securities by the Company, of the use of the Preliminary Prospectus or Prospectus, and there is no current or pending, or to the Company's knowledge, contemplated or threatened action suit, inquiry, investigation or other proceedings for this purpose, and there is, to the best of the Company's knowledge, no grounds therefor;
- (aq) there is no current or pending, or to the best of the Company's knowledge, contemplated or threatened action, suit, inquiry, investigation or other proceeding by any securities commission, stock exchange or similar regulatory authority or any other competent authority relating to the Company or its directors, officers, other insiders or promoters;
- (rr) other than the Agent and its Sub-Agents, there is no person, firm or corporation acting or purporting to act at the request of the Company who is entitled to any brokerage or finder's fee in connection with the transactions contemplated herein, and in the event that any person, firm or corporation acting or purporting to act for the Company establishes a claim for any such fee from the Agent, the Company covenants to indemnify and hold harmless the Agent with respect thereto and with respect to all costs reasonably incurred in defence thereof;
- (ss) the minute books of the Company as provided to counsel to the Agent are complete and accurate in all material respects and contain the complete and accurate minutes of all meetings and all resolutions of the directors and shareholders thereof;
- (tt) all material facts relating to the Company and its assets, properties, liabilities, obligations, business, operations, affairs, prospects or condition (financial or otherwise) or its capital or control, has been fully disclosed to the Agent and its counsel, and any information

provided by the Company to the Agent and its counsel was complete and accurate and did not contain any misrepresentation or untrue statement of material fact or omit to state a material fact necessary in order to make such information not false or misleading in the circumstances in which it was made, and in the aggregate constitutes full, plain and true disclosure relating to the Company and the Securities; the directors and senior officers of the Company will have reviewed, and the directors of the Company will have duly approved, the Transaction Agreements, the Preliminary Prospectus and the Prospectus at the respective times each is filed with the securities regulators, and the directors of the Company will have duly approved the Agent's use and distribution of same in connection with the IPO;

- (uu) except as disclosed in the Preliminary Prospectus or Prospectus, to the knowledge of the Company after due enquiry, none of the directors, officers or shareholders of the Company or any of its associates or affiliates, and none of the advisors to the Company, has had any material interest, direct or indirect, in any continuing or existing material transaction or has any material interest, direct or indirect, in any proposed material transaction which, as the case may be, materially affected, is material to or will materially affect the Company; and
- (vv) the Company does not own or have an interest in any assets material to the Company other than as disclosed in the Preliminary Prospectus or Prospectus.

5.2 The representations and warranties of the Company contained in this Agreement shall be true and correct at the time of the IPO Closing as though they were repeated and made thereat.

6. Covenants of the Company

6.1 The Company covenants with the Agent and the Purchasers, as covenants that are intended to be contractually enforceable by the Agent and the Purchasers or any one or more of them against the Company notwithstanding that the Purchasers are not parties to this Agreement, that the Company shall:

- (a) allow the Agent and its counsel to conduct, and will otherwise cooperate with and facilitate the conduct of, all due diligence investigations in connection with the IPO, the Preliminary Prospectus and the Prospectus, the assets, properties, liabilities, obligations, business, operations, affairs, prospects and condition of the Company and the Company's insiders and promoters, which the Agent may require or deem advisable, acting reasonably;
- (b) prior to the IPO Closing, deliver to the Agent, at the Agent's request, the President's List;
- (c) timely file the Preliminary Prospectus and the Prospectus with, and use its best efforts to obtain receipts for the Preliminary Prospectus and the Prospectus from each of the securities regulatory authorities of the IPO Jurisdictions as soon as practicable, and notify the Agent in writing promptly upon obtaining such receipts;
- (d) prior to and up until the IPO Closing, continue to negotiate in good faith with the Vendors, and enter into before or concurrently with the IPO Closing, the Acquisition Transaction and any related agreements, including but not limited to the Share Purchase Agreement and Vendor Employment Agreements (the "**Acquisition Agreements**");

- (e) ensure that the terms and conditions of the Acquisition Agreements are substantially in the same form as previously provided to the Agent (to the extent previously provided to the Agent), and that any material amendments to the Acquisition Agreements that are materially adverse to the Company or its business will not be made without the prior written consent of the Agent, such consent not to be unreasonably withheld or delayed;
- (f) upon the IPO Closing, use commercially reasonable efforts to cause the License Holder to maintain all licenses and permits necessary for carrying on its business as described in the Prospectus for a period of at least two years from the date of the IPO Closing;
- (g) if any event or circumstances occur which result in the Preliminary Prospectus, the Prospectus or any Amendment containing any untrue statement of a material fact or omitting to state any material fact necessary to make the statements therein in the light of the circumstances under which they were made not misleading, or if it shall be necessary to amend or supplement the Prospectus to comply with the Applicable Securities Laws:
 - (i) promptly notify the Agent of any such event; and
 - (ii) prepare and file an Amendment which will correct such statement or omission or effect full compliance with the Applicable Securities Laws;
- (h) supply the Agent, without charge, with as many copies of the Preliminary Prospectus, the Prospectus, any Amendment, the Preliminary U.S. Private Placement Memorandum and the Final U.S. Private Placement Memorandum as it may request, promptly upon and in any event within three business days after such request, and such delivery shall constitute:
 - (i) the Company's authorization and consent to the Agent and any Sub-Agents to use the Preliminary Prospectus, the Prospectus, any Amendment, the Preliminary U.S. Private Placement Memorandum and the Final U.S. Private Placement Memorandum in connection with the distribution of the IPO Units; and
 - (ii) the Company's representation and warranty to the Agent and any Sub-Agents that the Preliminary Prospectus, the Prospectus, any Amendment, the Preliminary U.S. Private Placement Memorandum and the Final U.S. Private Placement Memorandum at the time of its filing (as applicable) and delivery to the Agent or Sub-Agents complied with the requirements of Applicable Securities Laws and that all statements and information contained therein contain no misrepresentation (except information provided by and relating solely to the Agent or Sub-Agents) and constitute full, true and plain disclosure of all material facts relating to the Company, the IPO and the Securities;
- (i) allow the Agent and its counsel to participate fully in the preparation and finalization of the Preliminary Prospectus, the Prospectus, any Amendment, the Preliminary U.S. Private Placement Memorandum and the Final U.S. Private Placement Memorandum, and shall ensure that the form and substance of each of those documents shall be satisfactory to the Agent and its counsel, acting reasonably;
- (j) prior to the Agent signing the certificate page of the Prospectus and any Amendment, deliver to the Agent an officers' certificate in form and content satisfactory to the Agent, dated the date of the Prospectus or any Amendment as the case may be, addressed to the

Agent and signed by the Chief Executive Officer and the Chief Financial Officer, certifying to the effect that:

- (i) each such officer has carefully examined the Prospectus or the Amendment, as the case may be;
- (ii) the Prospectus and in the case of an Amendment, the document(s) which it amends, contains full, true and plain disclosure of all material facts in relation to the Company, the IPO and the Securities; and
- (iii) since the respective dates as of which information is given therein:
 - (A) the Company has not incurred any material liabilities or obligations (absolute, accrued or contingent, whether financial or otherwise) or entered into any transaction not in the ordinary course of business;
 - (B) there has been no material change (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) in or affecting the assets, liabilities, obligations, business, operations, affairs, prospects, results of operations or financial condition (absolute, accrued, contingent or otherwise), or the capital or control of the Company;
 - (C) except as disclosed in the Prospectus, there is no current or pending (in respect of which proper notice has been served on the Company), or to the best of the knowledge, contemplated or threatened, action, suit, investigation inquiry or other proceeding to which the Company is subject or to which the property of the Company is subject that would result in any material adverse change in or have a material adverse effect on (actual, anticipated, threatened, proposed or prospective, whether financial or otherwise), the assets, liabilities, obligations, position, business, operations, affairs, prospects, results of operations or financial condition (absolute, accrued, contingent or otherwise), or the capital or control of the Company; and
 - (D) to the best of its knowledge, no event has occurred and there exists no state of facts that is required, under the Applicable Securities Laws or the terms of this Agreement to be set forth in an Amendment that has not been so set forth;
- (k) prior to the filing of the fully executed Prospectus, cause the Company's auditors to deliver to the Agent and its counsel a comfort letter in form and content satisfactory to the Agent, dated the date of the Prospectus and/or the date of receipt for the Prospectus by the appropriate securities regulatory authority and addressed to the Agent and signed by the auditor verifying the financial information and accounting data, and the accuracy of the financial, accounting, numerical and certain other information disclosed in the Prospectus; and such comfort letter shall also be delivered to the Agent with respect to any Amendment where the financial information and accounting data have changed;

- (l) at the time of the IPO Closing:
 - (i) deliver to the Agent an officers' certificate in form and content satisfactory to the Agent, dated the date of the IPO Closing, addressed to the Agent and signed by the Chief Executive Officer and the Chief Financial Officer, to the effect that:
 - (A) all of the representations and warranties of the Company in this Agreement, and any agreements, instruments, certificates or other documents delivered by it pursuant or supplemental thereto are true and correct in all material respects as of the time of the IPO Closing, with the same force and effect as if made as at the IPO Closing;
 - (B) all of the covenants and conditions of the Company in the Agreement, and any agreements, instruments, certificates or other documents delivered by it pursuant or supplemental thereto to be fulfilled and observed prior to the time of the IPO Closing, have been fulfilled and observed in all material respects as at the IPO Closing;
 - (C) as of the IPO Closing, the Prospectus provides full, true and plain disclosure of all material facts relating to the Company, the IPO and the Securities in accordance with the Applicable Securities Laws, and does not contain any misrepresentation or any untrue, false or misleading statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances in which they were made, not untrue, false or misleading;
 - (D) there is no current or pending, or to the best of the officers' knowledge, contemplated or threatened, action, suit, inquiry, investigation or other proceeding to which the Company is subject or to which the property of the Company is subject that would result individually or in the aggregate in any material adverse change in or have a material adverse affect on (actual, anticipated, threatened, proposed or prospective, whether financial or otherwise), the assets, properties, liabilities, obligations, business, operations, affairs, prospects, results of operations or financial condition (absolute, accrued, contingent or otherwise), or the capital or control of the Company, or on the Prospectus, the Transaction Agreements and any action taken or to be taken thereunder;
 - (E) there is no inquiry or other investigation or proceeding regarding the Company or its directors, officers or promoters, including but not limited to a review of the Public Record, being instituted or pending or, to the knowledge of the Company, contemplated or threatened, by the Exchange or any regulatory authority having jurisdiction;
 - (F) there is no order:
 - (1) ceasing, halting or suspending trading in any securities of the Company,
 - (2) ceasing, halting or suspending trading in any securities by any one or more directors, officers or promoters of the Company, or

(3) prohibiting the offer, sale, issue or delivery of the Securities,

that has been issued, and no proceedings for such purpose being instituted or pending or, to the knowledge of the Company, contemplated or threatened, by any regulatory authority having jurisdiction; and

(G) in addition, with respect to the officers' certificate for the IPO Closing, since the respective dates as of which information is given in the Prospectus and any Amendment:

(1) the Company has not incurred or accrued any material liabilities or obligations (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) or entered into any transaction not in the ordinary course of the business,

(2) there has been no material change (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) in or affecting the assets, liabilities, obligations, results of operations or financial position, business, operations, affairs, prospects, condition, capital or control of the Company, or

(3) to the best of its knowledge and information, no event has occurred and there exists no state of facts that is required, under the Applicable Securities Laws or the terms of this Agreement to be set forth in an Amendment that has not been so set forth,

and further addressing such other matters as the Agent may reasonably request;

(ii) cause the Company's counsel to deliver to the Agent a favourable legal opinion or opinions in respect of all matters relating to the Company, the Securities, the IPO, the Prospectus and the Listing as the Agent may reasonably request, in form and content satisfactory to the Agent and such legal counsel, acting reasonably, signed by such legal counsel, dated the date of the IPO Closing and addressed to the Agent, its counsel and the Purchasers;

(iii) cause the Company's U.S. counsel to deliver to the Agent a favourable legal opinion in respect of all U.S. securities laws matters as the Agent may reasonably request, in form and content satisfactory to the Agent and such legal counsel, acting reasonably, signed by such legal counsel, dated the date of the IPO Closing and addressed to the Agent, its counsel and the Purchasers; and

(iv) deliver such other confirmations, certificates, instruments and other documents as the Agent or its counsel may reasonably request, including but not limited to, a title opinion in respect of any material properties of the Company, a tax opinion with respect to the tax matters set forth in the Prospectus and "bring down" certificates of the Company's qualified person(s) and its auditor;

(m) as soon as reasonably possible, apply for and use its best reasonable efforts to obtain the Listing and have the common shares of the Company, including the IPO Shares, the IPO Warrant Shares, the Agent's Unit Shares and the Agent's Unit Warrant Shares, listed or

approved for listing, as the case may be, on the Exchange forthwith following the IPO Closing or otherwise on such terms and conditions as may be satisfactory to the Agent, and in any event submit all required documentation and perform such other actions as may be necessary or desirable to have such common shares listed on the Exchange within 14 days following the IPO Closing (or, if multiple closings, following the first such IPO Closing), and also notify the Agent in writing forthwith upon obtaining such Listing;

- (n) duly, punctually and faithfully fulfill all legal requirements to permit the creation, offering, sale and issuance of the Securities, the preparation, execution and delivery of the Preliminary Prospectus and the Prospectus, and the entering into, execution and delivery of the Transaction Agreements, including, without limitation, compliance with all corporate requirements and Applicable Securities Laws to enable the IPO Units and Agent's Warrants to be distributed pursuant to the Prospectus and in accordance with this Agreement, so that the Securities will constitute lawfully issued and outstanding and fully paid and non-assessable securities of the Company, and so that the Transaction Agreements are enforceable against the Company in accordance with their terms and the Company can lawfully satisfy its obligations under the Transaction Agreements;
- (o) ensure that, at the IPO Closing, (i) the IPO Shares, the IPO Warrants, the Agent's Warrants will be duly and validly authorized, created and issued; (ii) the IPO Shares when issued will be fully paid and non-assessable securities; (iii) the IPO Warrant Shares will be duly and validly reserved for issuance upon exercise of the IPO Warrants and duly and validly authorized and issued as fully paid and non-assessable securities when issued upon exercise of the IPO Warrants in accordance with the provisions of the IPO Warrant Certificates, and ensure that at all times following the IPO Closing until the exercise or expiry of all of the IPO Warrants, the Company has a sufficient number of common shares reserved and available for issuance to satisfy its obligation under the IPO Warrants; (iv) the Agent's Unit Shares will be duly and validly reserved for issuance upon exercise of the Agent's Warrants, and duly and validly authorized and issued as fully paid and non-assessable securities when issued upon exercise of the Agent's Warrants in accordance with the provisions of the Agent's Warrant Certificates, and ensure that at all times following the IPO Closing until the exercise or expiry of all of the Agent's Unit Warrants, the Company has a sufficient number of common shares reserved and available for issuance to satisfy its obligations under the Agent's Warrants; (v) the Agent's Unit Warrants will be duly and validly reserved for issuance upon exercise of the Agent's Warrants; and (vi) the Agent's Unit Warrant Shares will be duly and validly reserved for issuance upon exercise of the Agent's Unit Warrants and duly and validly authorized and issued as fully paid and non-assessable securities when issued upon exercise of the Agent's Unit Warrants in accordance with the provisions of the Agent's Warrant Certificates; and ensure that at all times following the IPO Closing until the exercise or expiry of all of the Agent's Unit Warrants, the Company has a sufficient number of common shares reserved and available for issuance to satisfy its obligations under the Agent's Unit Warrants;
- (p) duly, punctually and faithfully file with the securities regulatory authorities of the IPO Jurisdictions and the Exchange in respect of the IPO all required documents and filing fees and do all such acts and things required by the rules, policies or discretion thereof in order to obtain the approval for the IPO, the Preliminary Prospectus, the Prospectus and the Listing, all on such terms and conditions as may be mutually acceptable to the Company and the Agent, acting reasonably;

- (q) ensure that the creation, offer, sale and issuance of the Securities will fully comply with the requirements of the Applicable Securities Laws, including but not limited to the conduct of the IPO, the preparation and filing of the Preliminary Prospectus and the Prospectus, and the preparation, filing and payment of filing fees for, within the required time periods, all notices, forms, reports and filings in connection with the IPO to be made after the IPO Closing as the case may be;
- (r) during the period commencing on the date hereof and ending on the conclusion of the distribution of the IPO Units to the public, promptly inform the Agent of:
 - (i) any material change (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) in or affecting the assets, liabilities, obligations, business, operations, affairs, prospects, results of operations or financial position (absolute, accrued, contingent or otherwise), or capital or control of the Company, provided that if the Company is uncertain as to whether a change, occurrence or event of the nature referred to in this paragraph has occurred, the Company shall promptly inform the Agent of the full particulars of the change, occurrence or event giving rise to the uncertainty and shall consult with the Agent as to whether the occurrence is of such nature, and thereafter, the Company shall promptly file such new or correcting information or amendments, and other documents as circumstances may require and deliver to the Agent as many copies of such information, amendments and other documents as the Agent may reasonably request;
 - (ii) any change of any nature that would result in the Preliminary Prospectus, the Prospectus or any Amendment containing a misrepresentation, or which would result in any of such documents not complying with the Applicable Securities Laws;
 - (iii) any material change (actual, anticipated, threatened, proposed or prospective, whether financial or otherwise) in or affecting any of the representations and warranties of the Company made in this Agreement;
 - (iv) any communication to or from any securities commission, stock exchange, or similar regulatory authority or by any other competent authority relating to the Public Record or to the distribution of any of the Securities (including without limitation in relation to the Preliminary Prospectus and the Prospectus), or any request for information or action, and provide a copy thereof to the Agent;
 - (v) any request of any securities commission, stock exchange or similar regulatory authority or by any other competent authority for any information relating to the Company or its directors, officers, insiders or promoters; and provide a copy thereof to the Agent; or
 - (vi) the issuance by a securities commission, stock exchange or similar regulatory authority or by any other competent authority of any order to cease or suspend trading of any securities of the Company or of the institution or threat of institution of any proceedings for that purpose;
- (s) during the period commencing on the date hereof and ending on the conclusion of the distribution of the IPO Units to the public (or such longer period as may be specified in

the respective representation, warrant, covenant or condition), do all such acts and things required to ensure that:

- (i) all of the representations and warranties of the Company contained in this Agreement and any agreements, instruments, certificates or other documents delivered by it pursuant hereto or supplemental hereto remain true and correct at all times;
- (ii) all of the covenants and conditions to be satisfied and observed by the Company contained in this Agreement, and any agreements, instruments, certificates or other documents delivered by it pursuant hereto or supplemental hereto are satisfied and observed as soon as is practicable and thereafter remain satisfied and observed at all times; and
- (iii) all of the closing conditions in this Agreement are met and remain satisfied,

and otherwise refrain from doing all such acts and things that would result in any of the foregoing representations and warranties being untrue or incorrect, covenants and conditions being unsatisfied or unobserved or closing conditions being unmet;

- (t) at the time of the IPO Closing (or such longer period as may be specified in the respective representation, warrant, covenant or condition), do all such acts and things required to ensure that:
 - (i) all of the representations and warranties of the Company contained in the Share Purchase Agreement and any agreements, instruments, certificates or other documents delivered by it pursuant thereto or supplemental thereto remain true and correct in all material respects as at the IPO Closing; and
 - (ii) all of the covenants and conditions of the Company to be satisfied and observed on or before the time of the IPO Closing contained in the Share Purchase Agreement and any agreements, instruments, certificates or other documents delivered by it pursuant thereto or supplemental thereto have been satisfied and observed in all material respects (or waived) on or before the IPO Closing,

and otherwise refrain from doing all such acts and things that would result in any of the foregoing representations and warranties being untrue or incorrect in any material respects, the foregoing covenants and conditions being unsatisfied or unobserved or the foregoing closing conditions unmet;

- (u) duly and punctually perform in all material respects all the obligations to be performed by it under the Acquisition Agreements;
- (v) both before and after the IPO Closing, duly, punctually and faithfully comply in all material respects with the requirements of the Applicable Securities Laws and use reasonable commercial efforts to maintain its status as a "reporting issuer" not in default in the IPO Jurisdictions (and in any jurisdictions that it may subsequently become a "reporting issuer") until the exercise or expiry of the last of the Agent's Warrants or the Agent's Unit Warrants; provided that this clause shall not be construed as limiting or restricting the Company from completing a consolidation, amalgamation, arrangement, takeover bid or merger that would result in the common shares of the Company ceasing

to be listed and posted for trading on the Exchange or which would result in the Company ceasing to maintain its existence or carry on its business in the ordinary course, or ceasing to be a reporting issuer in those provinces and other Canadian jurisdictions where it is or becomes a reporting issuer, so long as the holders of common shares of the Company receive securities of an entity which is listed on a stock exchange in Canada, or cash, or the holders of the common shares of the Company have approved the transaction in accordance with the requirements of applicable corporate and securities laws and the policies of the Exchange;

- (w) both before and after the IPO Closing, duly, punctually and faithfully comply with the rules, regulations, policies, discretionary decisions and other requirements of the Exchange, and use reasonable commercial efforts to maintain the Listing until the exercise or expiry of the last of the Agent's Warrants or the Agent's Unit Warrants; provided that this clause shall not be construed as limiting or restricting the Company from completing a consolidation, amalgamation, arrangement, takeover bid or merger that would result in the common shares of the Company ceasing to be listed and posted for trading on the Exchange or which would result in the Company ceasing to maintain its existence or carry on its business in the ordinary course, or ceasing to be a reporting issuer in those provinces and other Canadian jurisdictions where it is or becomes a reporting issuer, so long as the holders of common shares of the Company receive securities of an entity which is listed on a stock exchange in Canada, or cash, or the holders of the common shares of the Company have approved the transaction in accordance with the requirements of applicable corporate and securities laws and the policies of the Exchange;
- (x) ensure that the proceeds of the IPO received by the Company (i) are used in all material respects for the purposes and in the manner set forth in the Prospectus, and (ii) will not be used to settle any liens or other charges of the Company, including those described in the Equipment Promissory Note and IP Promissory Note, in an amount or amounts greater than those set out thereunder respectively; and
- (y) save and, except as disclosed in the Prospectus, not settle any debt or other obligation owing by the Company to its insiders or their associates and affiliates (including but not limited to any interest thereon), as of the date of the IPO Closing, with any proceeds of the IPO.

7. Representations and Warranties of the Agent

7.1 The Agent represents and warrants to the Company, and acknowledges that the Company is relying on such representations and warranties in entering into this Agreement, that it:

- (a) holds all registrations, licenses and permits that are required for carrying on its business in the manner in which such business is being carried on and as contemplated hereby and is duly qualified to carry on business in the IPO Jurisdictions;
- (b) has good and sufficient right and authority to enter into this Agreement and complete its transactions contemplated under this Agreement on the terms and conditions set forth herein; and
- (c) is, and will remain until the completion of the IPO, appropriately registered under the Applicable Securities Laws in the IPO Jurisdictions so as to permit it to lawfully fulfill its

obligations hereunder and the Agent is, and will remain until the completion of the IPO, a participating organization of the Exchange in good standing.

7.2 The representations and warranties of the Agent contained in this Agreement shall be true and correct at the time of the IPO Closing as though they were made at the IPO Closing.

8. Covenants of the Agent

8.1 The Agent covenants with the Company that it shall:

- (a) conduct its activities in connection with the distribution of the IPO Units in compliance with the Applicable Securities Laws and fulfil all legal requirements to be fulfilled by it to act as the Company's agent in undertaking the IPO in the IPO Jurisdictions;
- (b) in respect of the IPO, not solicit or conduct selling efforts in any jurisdiction other than the IPO Jurisdictions;
- (c) use its best efforts to obtain subscriptions for the IPO Units, and cause the Purchasers to complete any forms and other documents required by the Applicable Securities Laws in connection with the completion of the IPO;
- (d) not make any representations or warranties with respect to the Company or the IPO Units other than as set forth in the Prospectus; and
- (e) subject to the completion of satisfactory due diligence by and on behalf of the Agent, take all steps as may be reasonably necessary to assist the Company in complying with the requirements of the securities regulatory authorities in the IPO Jurisdictions and in its application for the Listing.

9. Closing Conditions in Favour of the Agent and Purchasers

9.1 The following are conditions of the Agent's obligations under this Agreement and the Purchasers' obligations to complete the purchase of the IPO Units, which conditions the Company shall use reasonable best efforts to have fulfilled at or prior to the time of the IPO Closing and which conditions may be waived in writing, in whole or in part by the Agent, on its own behalf and on behalf of the Purchasers:

- (a) the Company having taken all actions required to be taken to duly and validly conduct the IPO, to offer, sell, create, reserve, issue and deliver the respective Securities as contemplated herein, to prepare, execute and deliver the Prospectus, and to enter into, execute, deliver and perform its obligations under the respective Transaction Agreements, including, without limitation:
 - (i) the passing of all requisite resolutions of the directors and, if required by law or the policies of the Exchange, shareholders of the Company and the satisfaction of all other corporate approvals and requirements;
 - (ii) the making of all necessary filings with the securities regulatory authorities of the IPO Jurisdictions and the Exchange; and

- (iii) the receipt from the securities regulatory authorities of the IPO Jurisdictions and any other third parties of any and all required authorizations, approvals and consents for the IPO and the Transaction Agreements, on such terms as may be mutually acceptable to the Company and the Agent, acting reasonably;
- (b) all of the representations and warranties of the Company in this Agreement and any agreements, instruments, certificates or other documents delivered by it pursuant or supplemental thereto being true and correct in all material respects as of the time of the IPO Closing, with the same force and effect as if made as at the IPO Closing;
- (c) all of the covenants and conditions of the Company in this Agreement and any agreements, instruments, certificates or other documents delivered by it pursuant or supplemental thereto to be fulfilled and observed prior to the time of the IPO Closing having been fulfilled and observed in all material respects (or waived) as at the IPO Closing;
- (d) all of the representations and warranties of each of the Company and, to the knowledge of the Company, the Vendors contained in the Acquisition Agreements and any agreements, instruments, certificates or other documents delivered by it pursuant thereto or supplemental thereto being true and correct in all material respects as of the time of the IPO Closing, with the same force and effect as if made as at the IPO Closing;
- (e) all of the covenants and conditions of each of the Company and the Vendors to be satisfied and observed or waived on or before the time of the IPO Closing contained in the Acquisition Agreements and any agreements, instruments, certificates or other documents delivered by it pursuant thereto or supplemental thereto having been satisfied and observed in all material respects or waived by the Company and, to the knowledge of the Company, the Vendors respectively on or before the IPO Closing;
- (f) as at the time of the IPO Closing:
 - (i) the Company being duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation, continuation, amalgamation or other formation;
 - (ii) there being no inquiry or other investigation or proceeding regarding the Company or its directors, officers or promoters, including but not limited to a review of the Public Record, being instituted or, pending (in respect of which proper notice has been served on the Company), to the knowledge of the Company, contemplated or threatened, by the Exchange or any regulatory authority having jurisdiction;
 - (iii) there being no order:
 - (A) ceasing, halting or suspending trading in any securities of the Company,
 - (B) ceasing, halting or suspending trading in any securities by any one or more directors, officers or promoters of the Company, or
 - (C) prohibiting the offer, sale, issue or delivery of the Securities,

being issued, and no proceedings for such purpose being instituted or, pending (in respect of which proper notice has been served on the Company), or, to the knowledge of the Company, contemplated or threatened, by any regulatory authority having jurisdiction; and

- (iv) since the respective dates as of which information is given in the Prospectus, except as disclosed in the Prospectus:
 - (A) the Company having not incurred any material liabilities or obligations (absolute, accrued or contingent, whether financial or otherwise) or entered into any transaction not in the ordinary course of business;
 - (B) there having been no material change (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) in or affecting the assets, liabilities, obligations, business, operations, affairs, prospects, results of operations or financial condition (absolute, accrued, contingent or otherwise), or the capital or control of the Company;
 - (C) there being no current or pending (in respect of which proper notice has been served on the Company), or, to the knowledge of the Company, contemplated or threatened, action, suit, investigation, inquiry or other proceeding to which the Company is subject or to which the property of the Company is subject that would result in any material adverse change in or have a material adverse effect on (actual, anticipated, threatened, proposed or prospective, whether financial or otherwise) the assets, liabilities, obligations, position, business, operations, affairs, prospects, results of operations or financial condition (absolute, accrued, contingent or otherwise), or the capital or control of the Company, or on the Prospectus, the Transaction Agreements and any action taken or to be taken thereunder; and
 - (D) no event having occurred and there existing no state of facts that is required, under the Applicable Securities Laws or the terms of this Agreement to be set forth in an Amendment that has not been so set forth;
- (g) the Company having delivered the requisite closing documents, officers' certificate, legal opinions, comfort letters and such other confirmations, certificates, instruments and other documents as the Agent may reasonably request pursuant this Agreement;
- (h) the creation, offer, sale, issuance and delivery of the Securities in accordance with the terms hereof fully comply with the requirements of applicable corporate laws and securities laws, including but not limited to the Applicable Securities Laws;
- (i) the Prospectus:
 - (i) having been filed with and accepted by the securities regulatory authorities in the IPO Jurisdictions,
 - (ii) being in compliance in all material respects with all the requirements of the Applicable Securities Laws, and

- (iii) containing full, true and plain disclosure of all material facts relating to the Company, the IPO and the Securities, in accordance with the Applicable Securities Laws, and not containing any misrepresentation or any untrue, false, or misleading statement of material fact or any omission to state any material fact necessary to make the statements therein, in light of the circumstances, not untrue, false, or misleading;
- (j) the Company having delivered to the Agent confirmation in writing from the Exchange conditionally accepting the Listing subject only to customary conditions and the receipt of customary documentation in connection therewith, and otherwise in form and content satisfactory to the Agent, acting reasonably; and
- (k) the Agent being satisfied with the results of its due diligence investigations, acting reasonably.

10. Closing

- 10.1 The IPO Closing shall be completed at the offices of Cassels Brock & Blackwell LLP, Suite 2200, 885 West Georgia Street, Vancouver, BC, V6C 3E8, at such time or times and on such date or dates as may be agreed upon by the Company and the Agent within the time period allowed by the Applicable Securities Laws. The IPO may be completed in one or more partial closings and each such closing shall be made in accordance with the terms hereof.
- 10.2 At the IPO Closing, the Agent shall deliver or cause to be delivered to the Company one or more certified cheques, bank drafts or wire transfers made payable to the order of the Company in an aggregate amount equal to (i) the gross proceeds of the IPO (plus any retainer and any amounts advanced by the Company to the Agent prior to the IPO Closing towards the payment of the Corporate Finance Fee and the Expenses), less (ii) the Agent's Commission, the Corporate Finance Fee and the Expenses incurred to date.
- 10.3 At the IPO Closing, the Company shall deliver or cause to be delivered to the Agent:
- (a) a certified copy of the directors' resolutions approving the IPO, the Preliminary Prospectus, the Prospectus or any Amendment, the Transaction Agreements, the creation, reservation, offer and sale (as the case may be) of the Securities issued or issuable in connection with the IPO, and such other matters in relation therewith as counsel may deem necessary or appropriate, acting reasonably;
 - (b) a certified copy of the constating documents of the Company;
 - (c) a copy of the receipt for the Prospectus from the securities regulatory authority of each IPO Jurisdiction;
 - (d) a copy of the conditional approval for the Listing from the Exchange;
 - (e) a copy of all other authorizations, consents, approvals and other documents in respect of the IPO (including but not limited to the satisfaction of the conditions thereof), the Preliminary Prospectus and Prospectus, and Transaction Agreements that the Agent may reasonably request;
 - (f) a copy of this Agreement, duly and validly executed by the Company;

- (g) certificates representing the IPO Shares (or confirmation that any IPO Shares not represented by certificates have been delivered in electronic book entry form through CDS) sold pursuant to the IPO, as applicable, in such amounts and registrations as requested by the Agent;
- (h) certificates representing the IPO Warrants (or confirmation that any IPO Warrants not represented by certificates have been delivered in electronic book entry form through CDS) sold pursuant to the IPO, as applicable, in such amounts and registrations as requested by the Agent;
- (i) certificates representing the Agent's Warrants, as applicable, in such amounts and registrations as requested by the Agent; and
- (j) the comfort letters, legal opinions, officers' certificates and such other certificates, instruments and documents that may be requested by the Agent, acting reasonably, pursuant to the terms of this Agreement.

10.4 At the IPO Closing, all documents and payments shall be held in trust by the Company's and the Agent's respective counsel until all documents and payments have been delivered and both parties have instructed their respective counsel to release the documents, and thereafter the documents and payments shall be released to the parties entitled thereto.

10.5 All of the representations, warranties and covenants of the Company contained in this Agreement and contained in any agreement, instrument or other documents delivered by the Company pursuant to this Agreement shall survive the purchase and sale of the IPO Units and the issue of the Agent's Warrants, and shall continue in full force and effect unaffected by any subsequent exercise, disposition or acquisition of any of the Securities, as the case may be, for a period expiring on the exercise or expiry of the last of the Agent's Warrants or such longer period as may be specified in the respective representation, warranty or covenant. The Agent and the Purchasers are entitled to rely on the aforesaid representations, warranties and covenants of the Company notwithstanding any investigation which the Agent or the Purchasers may undertake or which may be undertaken on their behalf.

11. Expenses

11.1 Whether or not the transactions contemplated by this Agreement proceed or complete, the Corporate Finance Fee plus GST; the costs and expenses of or incidental to the creation, issue and offering of the IPO Units including the fees and expenses of counsel, auditors, qualified persons, consultants and other experts retained for the Company; and subject to section 11.2 below, all expenses (the "**Expenses**") reasonably incurred by the Agent in connection with the IPO and the Agent's due diligence including without limitation the legal expenses of the Agent, the cost of printing and delivering the certificates for the IPO Units, the fees and disbursements of the transfer agent, the cost of preparing, printing and delivering the Preliminary Prospectus and Prospectus to and by the Agent and the associated fees prescribed by the Applicable Securities Laws in connection with the IPO and the application for and obtaining of the Listing shall be paid by the Company. The Company will pay the Corporate Finance Fee, the expenses incurred by the Agent and the Agent's legal expenses from time to time as requested by the Agent by bank draft or certified cheque payable to the Agent or counsel to the Agent or in such other manner as is acceptable to the Agent (of which a non-refundable amount of \$15,750 including GST has been received by the Agent).

11.2 The legal expenses of the Agent in respect of due diligence and the preparation of the Transaction Agreements, the Preliminary Prospectus and the Prospectus shall not exceed \$40,000 (excluding disbursements and taxes) without the prior consent of the Company, which consent shall not be unreasonably withheld. The Agent acknowledges receipt of \$15,000 from the Company as a retainer for such expenses. Cumulative expenses (other than for legal fees or legal disbursements) exceeding \$10,000 will be subject to prior consent of the Company.

12. Garnishing Orders

12.1 If at any time, up to and including the IPO Closing, the Agent receives a garnishing order or other form of attachment purporting to garnish or attach, in respect of a debt alleged of the Company, a part or all of the subscription price of the IPO Units, the Agent may pay the amount purportedly attached or garnished into court.

12.2 Any payment by the Agent into court contemplated in this section is deemed to have been received by the Company as payment by the Agent against the subscription price of the IPO Units to the extent of the amount paid, and the Company is bound to issue and deliver the IPO Units proportionately to the amount paid by the Agent.

12.3 The Agent is not bound to ascertain the validity of any garnishing order or attachment, or whether in fact it attaches any monies held by the Agent, and the Agent may act with impunity in replying to any garnishing order or attachment.

12.4 Subject to Section 13 hereof, the Company will release, indemnify and save harmless the Agent in respect of all damages, costs, expenses or liability arising from any reasonable actions of the Agent under this section.

13. Indemnity and Contribution

13.1 The Company shall protect, indemnify and hold harmless the Agent and any Sub-Agents, any subsidiaries and affiliates thereof and their respective directors, officers, shareholders, partners, employees, agents, solicitors and any associates thereof (the "**Indemnified Parties**" and individually, an "**Indemnified Party**") from and against any and all actual or threatened claims, actions, suits, investigations, proceedings, losses, costs, charges, expenses (including legal), payments and other damages, liabilities and obligations, but excluding loss of profit, punitive damages, and consequential losses which they may directly or indirectly suffer or incur by reason of the IPO, the Transaction Agreements, the Preliminary Prospectus or the Prospectus and any Amendment, including but not limited to:

- (a) the Company not complying with any requirement of any laws, including the Applicable Securities Laws, or any other requirement of a competent regulatory authority, in connection with the IPO, the Prospectus or the Transaction Agreements;
- (b) the Company failing to obtain or satisfy the conditions of any requisite regulatory or third party authorization, consent or approval for the IPO, the Prospectus or the Transaction Agreements;
- (c) any information or statement (except relating solely to and supplied by the Agent) contained in the Public Record, Preliminary Prospectus or Prospectus, any amendment thereto or in any supplemental, additional or ancillary material, information, statement, notice, report or other instrument or document that may be filed by or on behalf of the

Company under the Applicable Securities Laws prior to the IPO Closing being or alleged to be a misrepresentation;

- (d) the omission or alleged omission to state in the Public Record, Preliminary Prospectus or Prospectus, any amendment thereto or in any supplemental, additional or ancillary material, information, statement, notice, report or other instrument or document that may be filed by or on behalf of the Company under the Applicable Securities Laws prior to the IPO Closing, any material fact or material information (except relating solely to and supplied by the Agent) required to be stated therein or necessary to make any statements therein not incomplete, untrue, incorrect or misleading in light of the circumstances under which it was made;
- (e) the Company failing to satisfy or comply with any of the provisions of any of the Transaction Agreements or any instrument or document pursuant to or supplemental thereto, including but not limited to any breach or default under any representation, warranty or covenant herein or therein contained;
- (f) any order, inquiry, investigation, proceeding or other action is made, instituted, contemplated or threatened by any regulatory authority or other competent authority into the affairs, records or accounts of the Company; and
- (g) any prohibition affecting the distribution or trading of the IPO Shares or any other of the Securities, which may be ordered by any one or more competent authorities if such prohibition is based on any statement or omission made by the Company in the Prospectus, any amendment thereto or in any supplemental, additional or ancillary material, information, statement, notice, report or other instrument or document that may be filed by or on behalf of the Company under the Applicable Securities Laws prior to the IPO Closing.

13.2 If any claim is asserted against an Indemnified Party in respect of which indemnity may be sought from the Company pursuant to the provisions hereof, or if any such potential claim comes to the knowledge of an Indemnified Party, the Indemnified Party concerned shall notify the Company in writing as soon as possible of the nature of such claim, always provided that the failure to so notify shall not affect the Company's liability under this paragraph (except to the extent that such failure has materially and adversely affected the Company's ability to reduce the amount of such claim), and the Company shall be entitled (but not required) to assume the defence thereof at its expense. Any such defence shall be through legal counsel reasonably acceptable to the Indemnified Party and no admission of liability or settlement shall be made by the Company or the Indemnified Party without, in each case, the prior written consent of all the parties hereto, such consent not to be unreasonably withheld or delayed. An Indemnified Party shall have the right to employ separate counsel in any such claim and participate in the defence thereof but the fees and expenses of such counsel shall be at the expense of the Indemnified Party unless:

- (a) the employment of such counsel has been authorized by the Company;
- (b) the Company determines to but fails to assume the defence of such claim on behalf of the Indemnified Party within a reasonable period of receiving notice of such claim, provided that the expiration of such period shall be deemed to occur on the second clear business day immediately preceding the date by which the Indemnified Party is required by law (in the absence of agreement to the contrary) to take action (such as the filing of an appearance or its equivalent) in connection with defending such claim; or

- (c) the Indemnified Party shall have been advised by counsel that representation of the Company and Indemnified Party by the same counsel would be inappropriate due to actual or potential differing interests between them or the nature of one or more legal defences that are or may be available to the Indemnified Party or the Company that are different from or in addition to those available to the other,

and in each such case the Company shall not have the right to assume the defence of such claim on behalf of the Indemnified Party but shall be liable to pay the reasonable fees and expenses of counsel for the Indemnified Party. The indemnity herein provided shall remain in full force and effect until all possible liability of the Indemnified Parties arising out of the transactions contemplated herein is extinguished by operation of law, and shall not be limited or affected by any other right to indemnity or contribution which any Indemnified Party may have by statute or otherwise at law, and shall not be limited or affected by any other right to indemnity or contribution obtained by an Indemnified Party from any other person. To the extent that any Indemnified Party is not a party to this Agreement, the parties acknowledge and agree that the Agent shall obtain and hold the rights and benefits of the indemnity herein provided in trust for and on behalf of such Indemnified Party.

- 13.3 The Company consents to personal jurisdiction and service and venue in any court in the IPO Jurisdictions which any claim which is subject to indemnification hereunder is brought against any Indemnified Party, and to the assignment of the benefit of this section to any Indemnified Party for the purpose of enforcement.
- 13.4 If a court of competent jurisdiction or a regulatory authority determines in a final judgment or ruling, respectively, from which no appeal can be made, that any losses, costs, damages, liabilities or other obligations resulted from the actions or conduct taken or not taken by the Indemnified Party dishonestly, illegally, fraudulently, in bad faith or through gross negligence or wilful misconduct, the rights of indemnity contained herein shall not apply to the extent of the losses, costs, damage, liabilities or other obligations caused by such actions or conduct taken or not taken.
- 13.5 If the indemnity provided for in this Article 13 is declared by a court of competent jurisdiction to be illegal or unenforceable as being contrary to public policy or for any other reason, the Agent and the Company shall contribute to the aggregate of all losses, costs, charges, expenses (including legal), payments and other damages, liabilities and obligations of the nature provided for above such that the Agent shall be responsible for that portion represented by the percentage that the Agent's Commission received by the Agent under this Agreement bears to the gross proceeds realized from the IPO and from Purchasers not on the President's List, and the Company shall be responsible for the balance, provided that, in no event shall the Agent be responsible for an amount in excess of the Agent's Commission and Corporate Finance Fee. Notwithstanding the foregoing, any person determined to be, by a court of competent jurisdiction or a regulatory authority in a final judgment or ruling, respectively, from which no appeal can be made, (i) guilty of fraudulent misrepresentation or wilful misconduct; (ii) acting dishonestly, illegally, fraudulently or in bad faith; or (iii) grossly negligent, shall not be entitled to or contribution from any other party under this Agreement. Any party entitled to contribution will, promptly after receiving notice of commencement of any claim, action, suit, investigation or proceeding against such party in respect of which a claim for contribution may be made against another party or parties under this section, notify such party or parties for whom contribution may be sought. In no case shall such party from whom contribution may be sought be liable to contribute pursuant to this section unless such notice shall have been provided, but the omission to so notify such party shall not relieve the party from whom contribution may be sought from

any other obligation it may have otherwise than under this section. The right to contribution provided in this section shall be in addition to and not in derogation of any other right to contribution which the Agent may have by statute or otherwise by law.

14. Termination

14.1 The Agent shall be entitled, at its option, to terminate its obligations under this Agreement and the IPO, and the Purchasers' obligations to otherwise purchase the IPO Units, without liability on its part, by notice to that effect delivered to the Company at any time prior to the IPO Closing if:

- (a) any of the representations or warranties made by the Company herein or in the other Transaction Agreements is or has become false in any material respect;
- (b) the Company is in default under, breach of or fails to comply with, any material term, condition or provision of this Agreement, the other Transaction Agreements or the Acquisition Agreements;
- (c) the Agent is not satisfied, acting reasonably, with the results of its due diligence investigations;
- (d) the Agent is of the reasonable opinion, in its sole discretion, that the IPO Units cannot be profitably marketed;
- (e) there shall occur or come into effect any event, condition or circumstance which constitutes, in the sole opinion of the Agent, acting reasonably, a material change (actual, anticipated, contingent, proposed or threatened, whether financial or otherwise) in or affecting the assets, liabilities, obligations, business, operations, affairs, prospects, results of operations or financial condition (absolute, accrued, contingent or otherwise), or in the capital or control of the Company, which would reasonably be expected to have a material adverse effect on the business of the Company or the market price or value of the IPO Units, or the marketability of the Securities;
- (f) there is instituted or threatened any inquiry, investigation or other proceeding (whether formal or informal) by any securities regulatory authority in relation to the Company or any of the Company's directors or officers which in the sole opinion of the Agent, acting reasonably, seriously affects or may seriously affect the IPO or any distribution or trading of the Securities;
- (g) any order to cease, halt or suspend trading in the securities of the Company, or an order to cease, halt or suspend trading against any one or more directors, officers or promoters of the Company, is made, instituted or threatened by a securities regulatory authority (including the Exchange) or other competent authority having jurisdiction;
- (h) there should develop, occur or come into effect any catastrophe of national or international consequence or any action, governmental law or regulation, inquiry or other occurrence of any nature whatsoever which, in the sole opinion of the Agent, acting reasonably, seriously affects or may seriously affect the financial markets, the business of the Company, the market for the Company's securities, the Agent's ability to perform its obligations under this Agreement or a Purchaser's decision to purchase the IPO Units;

- (i) any new or amended Prospectus discloses information which, in the sole opinion of the Agent, acting reasonably, may result in the subscribers for a material number of IPO Units exercising their rights under Applicable Securities Laws or otherwise to withdraw from or rescind their purchase thereof at any time prior to the IPO Closing; or
 - (j) following a consideration of the business, affairs, operations, properties, products, assets, history or prospects of the Company (financial or otherwise), or its principals and promoters, or the state of the financial markets in general, or the state of the market for the Company's securities in particular, the Agent reasonably determines, in its sole discretion, that it is not in the interest of the Purchasers to complete the purchase and sale of the IPO Units.
- 14.2 The Agent may waive, in whole or in part, or extend the time for compliance with, any terms and conditions of this Agreement without prejudice to its rights in respect of any other terms and conditions of this Agreement or any other or subsequent default, breach or non-compliance by the Company of the terms and conditions of this Agreement provided, however, that any waiver or extension must be in writing and signed by the Agent in order to be binding upon it. If the Agent terminates this Agreement and the Purchasers' obligations to otherwise purchase the IPO Units pursuant to this section, there shall be no further liability on the part of the Agent or the Purchasers. Notwithstanding the termination of this Agreement pursuant to this section, the provisions of Article 11 "Expenses", Article 12 "Garnishing Orders", Article 13 "Indemnity and Contribution" and Article 14 "Termination" shall survive such termination. The right of the Agent to terminate its obligations under this Agreement is in addition to such other remedies as it has or may have in respect of any default, breach or non-compliance by the Company in respect of any provision of or matter contemplated by this Agreement.

15. Right of First Refusal

- 15.1 The Company shall notify the Agent of the terms of any further brokered financing (the "**Financing**") that the Company requires or proposes to conduct during the twelve (12) months following the date of the IPO Closing and the Agent shall, subject to section 15.4 below, have a right of first refusal (the "**Right of First Refusal**") to act as the Company's lead agent in respect of any and all such Financings based on industry standard terms on the terms set out in the notice delivered to the Agent.
- 15.2 The Right of First Refusal may be exercised by the Agent within 10 calendar days following the receipt of the notice from the Company referred to in section 15.1 hereof by notifying the Company that it will provide the Financing on the terms set out in the notice to the Agent.
- 15.3 If the Agents fail to give the notice contemplated by section 15.2 hereof to the Company within the requisite 10 calendar days, the Company will then be free to make other arrangements to obtain the Financing from another source on the same terms or on terms no less favourable to the Company without any further obligations under this Article 15 to the Agent with respect to the Financing.
- 15.4 The Right of First Refusal in respect of additional Financings within the twelve (12) month period shall continue to be in effect if the Agent fails to exercise the Right of First Refusal in respect of the Financing.

16. Press Releases

- 16.1 Subject to the requirements of applicable laws, any press release of the Company relating to the IPO will be provided to the Agent not less than 24 hours in advance of its release, and the Company will use its commercially reasonable efforts to agree to the form and content thereof with the Agent prior to the release thereof.

17. Alternative Business Transactions

- 17.1 If the IPO is not completed as a result of the Company's decision to pursue an alternative business transaction on or before the date that is forty-five (45) days from the date of this Agreement, the Company shall pay the Agent an amount equal to the Agent's Commission, the Corporate Finance Fee and the Agent's Warrants that would otherwise have been earned by the Agent assuming the entire IPO were completed together with the Expenses incurred to that date. An "alternative business transaction" includes financing which has the effect of replacing the IPO, the issuance of securities of the Company in excess of 20% of the total value or number of securities currently outstanding or a business transaction involving a change of control of the Company or any material subsidiary including a merger, amalgamation, arrangement, take-over bid, insider bid, reorganization, joint venture, sale of all or substantially all assets, exchange of assets or similar transaction. An "alternative business transaction" does not include a financing arranged by the Company that is supplementary to the IPO contemplated herein. For greater certainty, in the event that the Agent shall avail itself of the provisions of Article 14 hereof, the Company will be free to pursue other methods of financing, in which case, the Company will not be responsible for the Agent's Commission, Corporate Finance Fee or the Agent's Warrants payable under this Agreement except for the Expenses referred to in Article 11 incurred to that date.

18. Miscellaneous

- 18.1 All information, data, advice and opinions furnished to the Agent, and furnished by the Agent to its counsel, in connection with the Agent's engagement hereunder, will be treated as confidential (except such information, data, advice and opinions which are now or hereafter become publicly available or publicly known from time to time, other than as a result of improper disclosure by the Agent, or are required by law or legal proceedings to be disclosed) and will be used by the Agent only in connection with the Agent's engagement hereunder. In connection with the Agent's activities hereunder, the Company may from time to time specifically authorize the Agent (including verbally) to discuss the information, data, advice and opinions with or deliver it to third parties, on the basis that the confidentiality of such information, data, advice and opinions will be maintained and preserved by such third parties.
- 18.2 Any notice or other communication to be given hereunder shall be in writing and delivered or telecopied as follows:

- (a) if to the Company to:

New Leaf Ventures Inc.
Suite 2200, 885 West Georgia Street
Vancouver, BC V6C 3E8
Attention: Mr. Mike Stier, CEO and Director
Email: mike@greendropcapital.com

with a copy to (which shall not constitute notice hereunder):

Cassels Brock & Blackwell LLP
Suite 2200, 885 West Georgia Street
Vancouver, BC V6C 3E8
Attention: Deepak Gill
E-mail: dgill@cassels.com

(b) if to the Agent to:

Mackie Research Capital Corporation
Suite 1920, 1075 West Georgia Street
Vancouver, BC V6E 3C9
Attention: Jovan Stupar, Managing Director
Facsimile: (778) 373-4101

with a copy to (which shall not constitute notice hereunder):

Vantage Law Corporation
Suite 1120 – 625 Howe Street
Vancouver, BC V6C 2T6
Attention: John Rhee
Facsimile: (604) 428-5123

Any such notice or other communication shall be deemed to have been given and received on the day of delivery if delivered, and the first day after being telecopied if telecopied, always provided that if such day is not a business day in the location where it is telecopied or delivered, it shall be deemed to have been given and received on the first business day thereafter.

- 18.3 This Agreement constitutes the entire agreement between the parties with respect to its subject matter, and supersedes any prior agreements with respect thereto between the parties including the engagement letter dated March 8, 2019 between the Company and the Agent. The parties shall execute and deliver any and all such further instruments and other documents and perform any and all such further acts and other things as may be necessary or desirable to carry out the intent of this Agreement.
- 18.4 Any amendments hereto or waivers in respect hereof shall only be effective if made in writing and executed by the parties or the person giving the waiver, as the case may be. The Agent may waive in whole or in part any breach of, default under or non-compliance with any representation, warranty, term or condition of this Agreement, or extend the time for compliance, without prejudice to any other rights in respect of any other representation, warranty, term or condition of this Agreement or any breach of, default under or non-compliance with them. No waiver of any provision shall constitute a waiver of any other provision or act as a continuing waiver unless such is expressly provided for.
- 18.5 If one or more of the provisions contained in this Agreement is determined to be invalid, illegal or unenforceable in any respect, such provision shall either be severed from this Agreement or this Agreement shall be construed as if such provision had never been contained in it.
- 18.6 This Agreement, any amendment, addendum or supplement hereto, and all other instruments and documents relating hereto shall be governed by and construed in accordance with the laws of the Province of British Columbia governing contracts made and to be performed wholly therein, and without reference to its principles governing the choice or conflict of laws. The parties hereto

irrevocably attorn and submit to the exclusive jurisdiction of the courts of the Province of British Columbia, sitting in the City of Vancouver, with respect to any dispute related to or arising from this Agreement.

- 18.7 This Agreement may be executed in one or more counterparts, all of which when so executed shall constitute one and the same Agreement, bearing the date set forth on the face page hereof notwithstanding the date of execution or delivery. This Agreement and any counterpart thereof may be delivered by telecopy, facsimile or email and when so delivered shall be deemed to be an original.
- 18.8 The terms and provisions of this Agreement shall be binding upon, and enure to the benefit of, the Company and the Agent and their respective successors and permitted assigns, provided that, except as herein provided, this Agreement shall not be assignable by any party without the written consent of the others.
- 18.9 Time shall be of the essence hereof.

[Signature page follows]

If this Agreement accurately reflects the terms of the transaction which the Agent and the Company are to enter into, and if such terms are agreed to by the Company, please communicate acceptance by executing a copy of this letter where indicated below and returning it to the Agent upon such execution. Upon such execution and delivery, this Agreement shall constitute a binding agreement between the Company and the Agent.

Yours truly,

MACKIE RESEARCH CAPITAL CORPORATION

Per: signed "Jovan Stupar"
Authorized Signatory

Accepted as of the date set out on the first page of this Agreement.

NEW LEAF VENTURES INC.

Per: signed "Michael Stier"
Authorized Signatory

SCHEDULE "A"
COMPLIANCE WITH UNITED STATES SECURITIES LAWS

As used in this Schedule "A" and Annex 1 to this Schedule "A", capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement to which this Schedule "A" is annexed and the following terms shall have the meanings indicated:

"affiliate" means an "affiliate" as that term is defined in Rule 405 under the U.S. Securities Act.

"Directed Selling Efforts" means "directed selling efforts" as that term is defined in Regulation S.

"Foreign Issuer" means "foreign issuer" as that term is defined in Regulation S.

"General Solicitation" and **"General Advertising"** have the meanings ascribed to them by Rule 502(c) of Regulation D.

"Offshore Transaction" means "offshore transaction" as that term is defined in Regulation S.

"Qualified Institutional Buyer" means "qualified institutional buyer" as that term is defined in Rule 144A.

"Rule 144A" means Rule 144A under the U.S. Securities Act.

"Substantial U.S. Market Interest" means "substantial U.S. market interest" as that term is defined in Regulation S.

"U.S. Exchange Act" means the United States Securities Exchange Act of 1934, as amended.

"U.S. Placee" means a U.S. Person for whose account or benefit the IPO Units are offered or sold, or a person to whom the IPO Units are offered or sold in the United States.

"U.S. Purchaser" means a Purchaser that is a U.S. Placee.

A. Representations, Warranties and Covenants of the Agent

The Agent (on its own behalf and on behalf of the U.S. Affiliate) acknowledges that the IPO Units have not been and will not be registered under the U.S. Securities Act or applicable state securities laws and may be offered and sold only in transactions exempt from or not subject to the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Agent (on its own behalf and on behalf of the U.S. Affiliate) represents, warrants, covenants and agrees to and with the Company with respect to their distribution of IPO Units in the United States that:

1. Neither the Agent nor the U.S. Affiliate has offered or sold nor will either of them offer or sell any IPO Units except (a) in an Offshore Transaction in accordance with Rule 903 of Regulation S or (b) in the United States or to U.S. Persons as provided in this Schedule "A". Accordingly, neither the Agent, nor the U.S. Affiliate, nor their respective affiliates or any persons acting on their behalf (including Sub-Agents) have engaged or will engage in any Directed Selling Efforts in the United States with respect to the IPO Units.
2. All offers and sales of IPO Units to U.S. Placees have been and will be made through the Agent's U.S. Affiliate, which is and at all relevant times was and will be a broker-dealer registered pursuant to Section 15(b) of the U.S. Exchange Act and in good standing with the Financial

Industry Regulatory Authority, Inc., and otherwise in compliance with all applicable U.S. broker-dealer requirements (including those of self-regulatory authorities) and securities laws, and all such offers and sales of IPO Units have been and will be made only in states of the United States where such U.S. Affiliate is registered or otherwise exempt from registration.

3. In connection with offers and sales of IPO Units to U.S. Placees, no form of General Solicitation or General Advertising has been or will be used. Neither the Agent, the U.S. Affiliate, their respective affiliates nor any persons acting on their behalf (including Sub-Agents) have engaged or will engage in any conduct involving a public offering within the meaning of Section 4(a)(2) of the U.S. Securities Act in connection with the offer or sale of the IPO Units to U.S. Placees.
4. Any offer to sell or solicitation of an offer to buy IPO Units that has been made or will be made to U.S. Placees was or will be made only to Accredited Investors or Qualified Institutional Buyers with whom, in each case, the Agent, the U.S. Affiliate or the Company has a pre-existing relationship prior to such offer or solicitation and a reasonable basis for believing them to be an Accredited Investor or a Qualified Institutional Buyer.
5. The Agent, through the U.S. Affiliate, shall inform all U.S. Placees that the IPO Units have not been and will not be registered under the U.S. Securities Act and the IPO Units are being offered and sold to such persons in reliance on Section 4(a)(2) of the U.S. Securities Act and/or Rule 506 (b) of Regulation D and similar exemptions under applicable state securities laws.
6. Each U.S. Placee has been or will be provided with a copy of one or both of the Preliminary U.S. Private Placement Memorandum or the Final U.S. Private Placement Memorandum, and no other written material has been or will be used in connection with the offer or sale of the IPO Units in the United States. Each U.S. Placee will, prior to the sale of IPO Units to such persons, be required to execute a U.S. Accredited Investor Agreement in the form of Exhibit "A" attached to the U.S. Memorandum or a U.S. QIB Agreement in the form of Exhibit "B" attached to the U.S. Memorandum. Prior to any offer or sale of IPO Units to each U.S. Placee, the Agent and the U.S. Affiliate each had or will have reasonable grounds to believe and will believe that each such offeree was an Accredited Investor or a Qualified Institutional Buyer, and at the IPO Closing shall continue to have reasonable grounds to believe and shall continue to believe that each U.S. Purchaser is an Accredited Investor or a Qualified Institutional Buyer.
7. All offers and sales of IPO Units made outside the United States to non-U.S. Placees by the Agent, the U.S. Affiliate, their respective affiliates or any persons acting on their behalf (including Sub-Agents) have been and will be made in Offshore Transactions.
8. If the Agent authorizes any Sub-Agent to offer and sell IPO Units to U.S. Placees through a U.S. Affiliate, the Agent will cause each such Sub-Agent to acknowledge in writing, for the benefit of the Company, its agreement to be bound by the provisions of this Schedule "A" in connection with all offers and sales of the IPO Units to U.S. Placees. The Agent will cause the U.S. Affiliate to comply, and will use its best efforts to ensure compliance by the Sub-Agents, with the provisions of this Schedule "A" as though such parties were directly party hereto.
9. Offers to sell and solicitations of offers to buy the IPO Units in the United States have been and will be made pursuant to and in accordance with exemptions from the registration or qualification requirements of all applicable state securities laws.

10. Neither the Agent nor the U.S. Affiliate, nor any person acting on its or their behalf, has taken, or will take, directly or indirectly, any action in violation of Regulation M under the U.S. Exchange Act in connection with the offer or sale of the IPO Units.
11. The Agent acknowledges that until 40 days after the IPO Closing, an offer or sale of the IPO Units within the United States by any dealer (whether or not participating in the IPO) may violate the registration requirement of the U.S. Securities Act if such offer or sale is made otherwise than in accordance with an exemption from the registration requirement of the U.S. Securities Act.
12. A reasonable time prior to the Closing, the Agent and the U.S. Affiliate will provide the Company with (a) a list of all U.S. Purchasers, (b) all executed U.S. Accredited Investor Agreements in the form attached as Exhibit "A" to the U.S. Memorandum, and (c) all executed U.S. QIB Agreements in the form attached as Exhibit "B" to the U.S. Memorandum.
13. At the Closing, the Agent and the U.S. Affiliate will provide a certificate, substantially in the form of Annex 1 attached hereto, relating to the manner of the offer and sale of the IPO Units to U.S. Placees, or the Agent and the U.S. Affiliate will be deemed to have represented to the Company that they did not offer or sell any IPO Units to U.S. Placees.
14. None of the Affiliate, the U.S. Affiliate or any director, executive officer, general partner, managing member or other officer of the Agent or the U.S. Affiliate participating in the IPO, nor any of its other officers or employees that have been or will be paid (directly or indirectly) remuneration for solicitation of U.S. Placees in connection with the sale of any IPO Units pursuant to Rule 506 of Regulation D under the U.S. Securities Act (each, an "**Agent Covered Person**" and, collectively, the "**Agent Covered Persons**") is subject to any Disqualification Event, except for a Disqualification Event (i) covered by Rule 506(d)(2) under Regulation D of the U.S. Securities Act and (ii) a description of which has been furnished in writing to the Corporation prior to the date hereof or, in the case of a Disqualification Event occurring after the date hereof, prior to the IPO Closing.

B. Representations, Warranties and Covenants of the Company

The Company represents, warrants, covenants to the Agent and the U.S. Affiliate that:

1. The Company is, and at the time of the IPO Closing will be, a Foreign Issuer and reasonably believes that there is no Substantial U.S. Market Interest in the common shares of the Company.
2. Except with respect to offers and sales in accordance with this Schedule "A" to Accredited Investors and Qualified Institutional Buyers in reliance on the exemptions from registration provided by Section 4(a)(2) of the U.S. Securities Act and/or Rule 506(b) of Regulation D, neither the Company nor any of its affiliates, nor any person acting on its or their behalf (other than the Agent, its affiliates (including, without limitation, the U.S. Affiliate), Sub-Agents and any person acting on their behalf, as to which no representation, warranty, covenant or agreement is made), has made or will make any offer to sell, or any solicitation of an offer to buy, any IPO Units to a U.S. Placee.
3. None of the Company or its affiliates or any person acting on its or their behalf (other than the Agent, its affiliates (including, without limitation, the U.S. Affiliate), Sub-Agents and any person acting on their behalf, as to which no representation, warranty, covenant or agreement is made) has offered or will offer to sell, or has solicited or will solicit offers to buy, IPO Units to U.S. Placees by means of any form of General Solicitation or General Advertising or in any manner

involving a public offering within the meaning of Section 4(a)(2) of the U.S. Securities Act.

4. Any offers and sales of IPO Units made outside the United States by the Company, any of its affiliates or any person acting on its or their behalf (other than the Agent, its affiliates (including, without limitation, the U.S. Affiliate), Sub-Agents and any person acting on their behalf, as to which no representation, warranty, covenant or agreement is made), have been and will be made in Offshore Transactions.
5. None of the Company, its affiliates, or any person acting on its or their behalf (other than the Agent, its affiliates (including, without limitation, the U.S. Affiliate), Sub-Agents and any person acting on their behalf, as to which no representation, warranty, covenant or agreement is made), has made or will make any Directed Selling Efforts in the United States with respect to the IPO Units.
6. The Company has not sold, offered for sale or solicited any offer to buy and will not sell, offer for sale or solicit any offer to buy, during the period beginning six months prior to the commencement of the IPO and ending six months after the completion of the IPO, any of its securities in the United States in a manner that would be integrated with and would cause the exemptions from registration provided by Section 4(a)(2) of the U.S. Securities Act and Rule 506(b) of Regulation D, or the exclusion from registration provided by Rule 903 of Regulation S, to be unavailable with respect to offers and sales of the IPO Units pursuant to this Schedule "A".
7. None of the Company, its affiliates, or any person acting on its or their behalf, has taken or will take any action that would cause the exemptions from the registration requirements of the U.S. Securities Act afforded by Section 4(a)(2) thereof or Rule 506(b) of Regulation D, or the exclusion from registration provided by Rule 903 of Regulation S, to be unavailable for offers and sales of the IPO Units pursuant to the Agreement to which this Schedule "A" is annexed.
8. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf (other than the Agent, its affiliates (including, without limitation, the U.S. Affiliate), any Sub-Agent and any person acting on their behalf, as to which the Company makes no representation, warranty, covenant or agreement) has taken or will take, directly or indirectly, any action in violation of Regulation M under the U.S. Exchange Act in connection with the offer or sale of the IPO Units.
9. The Company is not, and following the application of the proceeds of the sale of the IPO Units in the manner described in the Prospectus will not be, registered or required to be registered as an investment company under the United States Investment Company Act of 1940, as amended, and the rules and regulations promulgated thereunder.
10. The Company will, within the prescribed time periods, prepare and file any forms or notices required under the U.S. Securities Act or any state securities laws in connection with the sale of the IPO Units.
11. None of the Company or any of its predecessors or affiliates have been subject to any order, judgment or decree of any court of competent jurisdiction temporarily, preliminarily or permanently enjoining such person for a failure to comply with Rule 503 of Regulation D.
12. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the Offering, any beneficial owner of 20% or more of the Company's outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the U.S. Securities Act)

connected with the Company in any capacity at the time of sale of the IPO Units (each an “**Issuer Covered Person**” and, collectively, the “**Issuer Covered Persons**”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) of Regulation D (a “**Disqualification Event**”). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied with its disclosure obligations under Rule 506(e) of Regulation D, if applicable, and has furnished to the Agent and each U.S. Purchaser a copy of any disclosures required thereunder.

Annex 1

AGENT'S CERTIFICATE

This is Annex 1 to Schedule "A" to the Agency Agreement dated February ____, 2020 between New Leaf Ventures Inc. and Mackie Research Capital Corporation (the "Agency Agreement").

Capitalized terms used but not defined in this certificate have the meanings given to them in the Agency Agreement, including Schedule "A" thereto.

Pursuant to Section A.13. of Schedule "A" to the Agency Agreement, the undersigned Agent and the U.S. Affiliate hereby certify as follows:

1. All offers of IPO Units to U.S. Placees were made through the U.S. Affiliate;
2. The U.S. Affiliate is a duly registered broker or dealer pursuant to Section 15(b) of the U.S. Exchange Act and under the laws of each applicable state of the United States (unless exempted from the respective state's broker-dealer registration requirements), and was and is a member of, and in good standing with, the Financial Industry Regulatory Authority, Inc. on the date hereof and on the date of each offer and sale made by it in the United States, and all offers and sales of IPO Units in the United States have been effected by the U.S. Affiliate in accordance with all U.S. federal and state broker-dealer requirements;
3. Each U.S. Placee was provided with a copy of the U.S. Memorandum, and no other written material was used in connection with the offer or sale of the IPO Units in the United States;
4. Immediately prior to our transmitting the Preliminary U.S. Private Placement Memorandum or the Final U.S. Private Placement Memorandum to U.S. Placees, we had reasonable grounds to believe and did believe that each U.S. Placee was an Accredited Investor or a Qualified Institutional Buyer, and, on the date hereof, we continue to believe that each U.S. Purchaser is an Accredited investor or a Qualified Institutional Buyer;
5. We obtained from each U.S. Purchaser an executed U.S. Accredited Investor Agreement in the form of Exhibit "A" to the U.S. Memorandum or an executed U.S. QIB Agreement in the form of Exhibit "B" to the U.S. Memorandum, and we have delivered copies of the same to the Company;
6. No form of General Solicitation or General Advertising was used by us in connection with the offer of the IPO Units to U.S. Placees and no Directed Selling Efforts have been made by us in the United States; and
7. All offers and sales of the IPO Units to U.S. Placees have been conducted by us in accordance with the terms of the Agency Agreement, including Schedule "A" thereto.

Dated this ____ day of _____, 2020.

**MACKIE RESEARCH CAPITAL
CORPORATION**

[U.S. AFFILIATE]

Authorized Signing Officer

Authorized Signing Officer